Related Experiment Video
Updated: Dec 24, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Induction-remission response in peadiatric acute lymphoblastic leukaemia, Lahore protocol versus UKALL 2011 interim
Safia Khan1, Saadia Anwar2, Muhammad Farooq Latif3
1Pediatric Hematology Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Insights
Comparing treatment guidelines for acute lymphoblastic leukaemia (ALL) in children showed similar remission rates. However, early response significantly predicted remission only with the UK ALL-2011 guidelines.
Area of Science:
- Pediatric Hematology Oncology
- Clinical Trial Analysis
- Leukemia Treatment Protocols
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Optimizing induction-remission strategies is crucial for improving patient outcomes.
- Comparing international treatment guidelines can inform best practices.
Purpose of the Study:
- To compare the effectiveness of two distinct treatment protocols for acute lymphoblastic leukemia (ALL) in achieving induction-remission.
- To evaluate the association between rapid early response and induction-remission under different ALL treatment guidelines.
Main Methods:
- A retrospective cohort study involving 98 pediatric ALL patients treated between September 2014 and August 2015.
- Patients were divided into two groups: Group 1 (Lahore protocol) and Group 2 (UK ALL-2011 interim guidelines).
- Data collected included demographics, risk stratification, rapid early response, and induction-remission assessment, analyzed using SPSS.
Main Results:
- Induction-remission rates were comparable between the Lahore protocol (79%) and UK ALL-2011 guidelines (72%).
- A higher proportion of high-risk patients were in Group 1 (71%) compared to Group 2 (40%).
- Rapid early response was significantly associated with induction-remission in Group 2 (UK ALL-2011) but not in Group 1.
Conclusions:
- Induction-remission rates for pediatric ALL are similar across the compared treatment protocols.
- The UK ALL-2011 interim guidelines demonstrated a significant association between rapid early response and achieving remission.
- Early response assessment may be a more critical predictor of remission success under specific treatment protocols.
Objective:
To compare the outcome of induction-remission in acute lymphoblastic leukaemia patients treated according to two different guidelines.
Methods:
The descriptive retrospective cohort study was conducted at The Children's Hospital Lahore, Pakistan, and comprised clinical information sheets of acute lymphoblastic leukaemia patients from September 2014 to August 2015. Data regarding demographics, risk categorisation, rapid early response and induction-remission assessment was collected separately for Group 1 patients treated with Lahore protocol and Group 2 patients using United Kingdom acute lymphoblastic leukaemia-2011 interim guidelines. Data was analysed using SPSS version 20.0.
Results:
Of the 98 patients who had a median age of 6.4 years (interquartile range: 1.5-16 years), 48(49%) were in Group 1 and 50(51%) in Group 2. There were 14(29%) patients with standard risk in Group 1 while 34(71%) were high-risk. The corresponding numbers in Group 2 were 30(60%) and 20(40%) in Group 2. Rapid early response was noted in 18(37.5%) patients in Group 1 and 11(28%) in Group 2. Remission was achieved in 38(79%) patients in Group 1 and 36(72%) in Group 2. There was significant association of rapid early response with induction-remission in Group 2 (p<0.05) but not in Group 1 (p>0.05).
Conclusions:
Induction-remission rate was comparable in the two treatment groups, but significant association of rapid early response with induction-remission was observed only in patients treated using United Kingdom acute lymphoblastic leukaemia-2011 interim guidelines.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
